Pacific Biosciences Of Stock Performance
| PACB Stock | USD 1.85 0.05 2.78% |
On a scale of 0 to 100, Pacific Biosciences holds a performance score of 8. The company holds a Beta of 0.23, which implies not very significant fluctuations relative to the market. As returns on the market increase, Pacific Biosciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Pacific Biosciences is expected to be smaller as well. Please check Pacific Biosciences' downside deviation, total risk alpha, value at risk, as well as the relationship between the information ratio and treynor ratio , to make a quick decision on whether Pacific Biosciences' historical price patterns will revert.
Risk-Adjusted Performance
8 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Pacific Biosciences of are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak fundamental indicators, Pacific Biosciences sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Acquisition by Ericson William W. of 32179 shares of Pacific Biosciences at 1.65 subject to Rule 16b-3 | 09/03/2024 |
2 | Disposition of 98907 shares by Henry Christian O of Pacific Biosciences at 1.746 subject to Rule 16b-3 | 09/16/2024 |
3 | Acquisition by Livingston Randall S of 22821 shares of Pacific Biosciences subject to Rule 16b-3 | 09/27/2024 |
4 | Investors Are Invited To Join The Schall Law Firms Inquiry Into Pacific Biosciences of California Inc For Possible Securities Fraud | 10/04/2024 |
5 | PacBio Onso Short Read Sequencing Instrument Joins 10x Genomics Compatible Partner Program | 10/22/2024 |
6 | Acquisition by Ericson William W. of 25775 shares of Pacific Biosciences at 11.94 subject to Rule 16b-3 | 11/06/2024 |
7 | Pacific Biosciences of California Reports Q3 Loss, Misses Revenue Estimates | 11/07/2024 |
8 | Pacific Biosciences Q3 Earnings Taking a Look at Key Metrics Versus Estimates | 11/08/2024 |
9 | Pacific Biosciences of California Given New 6.00 Price Target at Scotiabank | 11/12/2024 |
10 | Pacific Biosciences of California, Inc. Among the Best Genomics Stocks to Buy Right Now | 11/20/2024 |
| Begin Period Cash Flow | 328.3 M |
Pacific |
Pacific Biosciences Relative Risk vs. Return Landscape
If you would invest 135.00 in Pacific Biosciences of on August 28, 2024 and sell it today you would earn a total of 50.00 from holding Pacific Biosciences of or generate 37.04% return on investment over 90 days. Pacific Biosciences of is currently generating 0.7105% in daily expected returns and assumes 6.6388% risk (volatility on return distribution) over the 90 days horizon. In different words, 59% of stocks are less volatile than Pacific, and 86% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Pacific Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pacific Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Pacific Biosciences of, and traders can use it to determine the average amount a Pacific Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.107
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | PACB | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.64 actual daily | 59 59% of assets are less volatile |
Expected Return
| 0.71 actual daily | 14 86% of assets have higher returns |
Risk-Adjusted Return
| 0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average Pacific Biosciences is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pacific Biosciences by adding it to a well-diversified portfolio.
Pacific Biosciences Fundamentals Growth
Pacific Stock prices reflect investors' perceptions of the future prospects and financial health of Pacific Biosciences, and Pacific Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pacific Stock performance.
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (2.28) % | ||||
| Operating Margin | (1.40) % | ||||
| Current Valuation | 979.37 M | ||||
| Shares Outstanding | 294.32 M | ||||
| Price To Earning | 197.88 X | ||||
| Price To Book | 1.17 X | ||||
| Price To Sales | 3.06 X | ||||
| Revenue | 200.52 M | ||||
| Gross Profit | 53.47 M | ||||
| EBITDA | (277.28 M) | ||||
| Net Income | (306.74 M) | ||||
| Cash And Equivalents | 834.34 M | ||||
| Cash Per Share | 3.69 X | ||||
| Total Debt | 933.93 M | ||||
| Debt To Equity | 1.51 % | ||||
| Current Ratio | 11.19 X | ||||
| Book Value Per Share | 1.66 X | ||||
| Cash Flow From Operations | (259.17 M) | ||||
| Earnings Per Share | (1.46) X | ||||
| Market Capitalization | 529.77 M | ||||
| Total Asset | 1.75 B | ||||
| Retained Earnings | (1.84 B) | ||||
| Working Capital | 647.02 M | ||||
| Current Asset | 110.54 M | ||||
| Current Liabilities | 38.18 M | ||||
About Pacific Biosciences Performance
By analyzing Pacific Biosciences' fundamental ratios, stakeholders can gain valuable insights into Pacific Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Pacific Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Pacific Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 140.02 | 158.79 | |
| Return On Tangible Assets | (0.37) | (0.39) | |
| Return On Capital Employed | (0.20) | (0.21) | |
| Return On Assets | (0.18) | (0.18) | |
| Return On Equity | (0.44) | (0.46) |
Things to note about Pacific Biosciences performance evaluation
Checking the ongoing alerts about Pacific Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Pacific Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pacific Biosciences is way too risky over 90 days horizon | |
| Pacific Biosciences may become a speculative penny stock | |
| Pacific Biosciences appears to be risky and price may revert if volatility continues | |
| Pacific Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 200.52 M. Net Loss for the year was (306.74 M) with profit before overhead, payroll, taxes, and interest of 53.47 M. | |
| Pacific Biosciences of currently holds about 834.34 M in cash with (259.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.69, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Pacific Biosciences has a frail financial position based on the latest SEC disclosures | |
| Over 83.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Pacific Biosciences of California, Inc. Among the Best Genomics Stocks to Buy Right Now |
- Analyzing Pacific Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pacific Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Pacific Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pacific Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pacific Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pacific Biosciences' stock. These opinions can provide insight into Pacific Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Pacific Stock analysis
When running Pacific Biosciences' price analysis, check to measure Pacific Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacific Biosciences is operating at the current time. Most of Pacific Biosciences' value examination focuses on studying past and present price action to predict the probability of Pacific Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacific Biosciences' price. Additionally, you may evaluate how the addition of Pacific Biosciences to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |